CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14+
SponsorChina-Japan Friendship Hospital

About this trial

Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly underutilized, especially in China.A number of quality improvements (QI) program have been established in several countries or hospitals.However,no exit effective protocol has been demonstrated well enough or adequate to drive breakthrough levels of improvement. A reliable and practical QI that can support hospitals or physicians in China is warranted.To evaluate the multifaceted quality improvement intervention effect in clinical setting, we will conduct a cluster-randomized clinical trial among China PUlmonary Thromboembolism REgistry Study (CURES) group, aiming to test whether it's applicable to real-world practice in China.

A multicenter, two-arms, open-label clinical trial has been designed to determine whether the system-wide multifaceted intervention could increase the rate of at-risk participants who received prophylaxis (RP) and decrease the incidence of any hospital-associated VTE in 90 days during and after hospital admission. .Selected hospital will be regarded as a cluster and randomized into interventional or control group.In interventional group, eligible hospitalized patients will receive a variety of the multifaceted quality improvement(QI) interventions since admitted in hospital.In control group, patients will receive no more than common recommended care or an existing policy.The primary outcomes are the proportion of appropriate prophylaxis in hospitalized patients and the incidence of HA-VTE in 90 days after hospital admission.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged ≥14 years

Have an expected hospital stay ≥72 hours for medical and/or surgical treatment

Written informed consent

Disqualifiers

Inability to be followed-up at until 3 months after randomization

Have participated in similar trials or are undergoing other clinical trials

Refuse or are unable to give informed consent

VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment

Trial design

Design model

Parallel

Treatments tested in this trial

  • The multifaceted interventions

    Other intervention

    1. An evidence-based clinical guideline and pathway in hospital. 2. A series Written care protocols for the implementation of performance measures. 3. A newly developed mobile application (mini-program) will be employed to facilitate venous thromboembolism (VTE) risk assessment and prophylaxis. Patients will scan a QR code to enroll in the program and be linked with their physician. Through the application, patients will complete standardized self-assessments of VTE risk, and physicians will receive periodic reminders indicating whether the assessment and prophylaxis orders have been completed.The application also provides educational modules and targeted messages for both patients and physicians, and enables interactive communication. 4. A quality-control team will receive weekly feedback reports to verify whether all enrolled patients underwent appropriate prophylaxis.

  • Routine VTE prophylaxis

    Other intervention

    Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices

Treatment groups

5,800 Participants
are divided into 2 treatment groups
Group A: The multifaceted QI interventionsExperimental treatment 1 intervention
Group B: Routine VTE prophylaxis in local clinical practiceActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of appropriate prophylaxis rate during hospitalization

The proportion of appropriate prophylaxis is defined as the number of appropriate prophylaxis among the patients at risk of VTE and without corresponding contraindications.

Time frame
90 days after hospital admission
2

The proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)

The incidence of HA-VTE is defined as the proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)

Time frame
90 days after hospital admission

Secondary outcomes

1

All-cause mortality

Proportion of participants who was dead(all-cause mortality)

Time frame
90 days after hospital admission
2

Proportion of complications related to the intervention

complications(i.e. major bleeding,minor bleeding, thrombocytopenia) related to the intervention

Time frame
90 days after hospital admission

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.